IQV Share Price | IQVIA Holdings, Inc. Stock Analysis & Recommendation

Q: What does IQVIA Holdings, Inc. do?

Overview:IQVIA Holdings, Inc. provides integrated information and technology-enabled healthcare services and operates in the Miscellaneous industry with a large-cap market capitalization.Financial Snapshot:Most recent Net Sales: 3,831 Million (Quarterly Results - Mar 2025) Most recent Net Profit: 249 Million (Quarterly Results - Mar 2025) Market-cap: USD 39,310.91 Million (Large Cap)Key Metrics:P/E: 29.00 Debt Equity: 2.08 Return on Equity: 22.52% Price to Book: 6.58Contact Details:Address: 4820 Emperor Blvd, DURHAM NC: 27703-8426 Tel: 1 919 9982000 Website: https://ir.iqvia.com/

Q: Is IQVIA Holdings, Inc. technically bullish or bearish?

As of 3 October 2025, the technical trend for IQVIA Holdings, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The daily moving averages are also bullish, supporting the overall positive stance. However, the weekly RSI is bearish, indicating some short-term weakness. The Bollinger Bands show a mildly bullish trend on the weekly and bullish on the monthly. The KST is bullish weekly but bearish monthly, and Dow Theory indicates no trend weekly and mildly bullish monthly. In terms of performance, IQVIA has outperformed the S&P 500 over the past week and month, with returns of 13.45% and 9.24% compared to 1.09% and 4.15% for the index, respectively. However, it has underperformed over the longer term, with a 1-year return of -10.80% versus 17.82% for the S&P 500. Overall, the current stance is bullish, driven by strong moving averages and MACD indicators, despite some mixed signals from RSI and KST.

Q: Is IQVIA Holdings, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for IQVIA Holdings, Inc. moved from very expensive to expensive. Based on the current metrics, the company appears to be overvalued. The P/E ratio stands at 29, which is significantly higher than the peer average of 29.20 for Laboratory Corp. of America Holdings and 27.82 for Quest Diagnostics, Inc. Additionally, the EV to EBITDA ratio of 15.15 is also above the peer average of 14.94 for Laboratory Corp. of America, indicating a premium valuation compared to its peers.In terms of returns, IQVIA has underperformed against the S&P 500 over the one-year and three-year periods, with returns of -12.54% and 12.90%, respectively, compared to the S&P 500's 14.08% and 81.19%. This underperformance further supports the conclusion that IQVIA Holdings, Inc. is currently overvalued in the market.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.57 M

Shareholding (Dec 2025)

FII

25.68%

Held by 473 FIIs

DII

35.74%

Held by 59 DIIs

Promoter

0.01%

How big is IQVIA Holdings, Inc.?

22-Jun-2025

As of Jun 18, IQVIA Holdings, Inc. has a market capitalization of $39.31 billion, with net sales of $15.50 billion and a net profit of $1.33 billion for the latest four quarters.

View full answer

What does IQVIA Holdings, Inc. do?

22-Jun-2025

IQVIA Holdings, Inc. provides integrated information and technology-enabled healthcare services, with a market capitalization of approximately $39.31 billion. As of March 2025, it reported net sales of $3.83 billion and a net profit of $249 million.

View full answer

Who are in the management team of IQVIA Holdings, Inc.?

22-Jun-2025

As of March 2022, the management team of IQVIA Holdings, Inc. is led by Mr. Ari Bousbib as Chairman, President, and CEO, with Dr. John Leonard serving as Lead Independent Director and a board that includes independent directors Ms. Carol Burt, Mr. John Connaughton, Mr. John Danhakl, and Mr. James Fasano.

View full answer

Is IQVIA Holdings, Inc. technically bullish or bearish?

07-Oct-2025

As of October 3, 2025, IQVIA Holdings, Inc. shows a bullish trend supported by strong moving averages and MACD indicators, despite a bearish weekly RSI and mixed signals from KST, while outperforming the S&P 500 in the short term but underperforming over the past year.

View full answer

Is IQVIA Holdings, Inc. overvalued or undervalued?

21-Oct-2025

As of October 17, 2025, IQVIA Holdings, Inc. is considered overvalued with a P/E ratio of 29, higher than its peers, and has underperformed the S&P 500 over the past one and three years.

View full answer

Compare IQVIA Holdings, Inc. with Similar Stocks

Laboratory Corp. of America Holdings Quest Diagnostics, Inc.Astrana Health, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Healthy long term growth as Operating profit has grown by an annual rate 25.95%

Flat results in Jun 25

With ROCE of 12.33%, it has a expensive valuation with a 2.78 Enterprise value to Capital Employed

Mojo Parameters

Stock DNA

Industry

Miscellaneous

Market cap

USD 41,519 Million (Mid Cap)

P/E

29.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

2.10

Return on Equity

21.91%

Price to Book

6.38

Revenue and Profits:

Net Sales:

4,359 Million

(Quarterly Results - Dec 2025)

Net Profit:

514 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-25.37%

6 Months

-12.69%

1 Year

-11.92%

2 Years

-34.58%

3 Years

-13.0%

4 Years

-27.05%

5 Years

-10.95%

IQVIA Holdings, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

7.50%

EBIT Growth (5y)

23.88%

EBIT to Interest (avg)

3.35

Debt to EBITDA (avg)

3.96

Net Debt to Equity (avg)

2.08

Sales to Capital Employed (avg)

0.75

Tax Ratio

18.95%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

9.82%

ROE (avg)

17.67%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

6.38

EV to EBIT

24.20

EV to EBITDA

16.12

EV to Capital Employed

2.73

EV to Sales

3.39

PEG Ratio

2.68

Dividend Yield

ROCE (Latest)

11.30%

ROE (Latest)

21.91%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 166 Schemes (38.54%)

Foreign Institutions

Held by 473 Foreign Institutions (25.68%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 10.13% vs 2.35% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 17.62% vs -6.82% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "4,359.00",
          "val2": "3,958.00",
          "chgp": "10.13%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "963.00",
          "val2": "925.00",
          "chgp": "4.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "193.00",
          "val2": "174.00",
          "chgp": "10.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-8.00",
          "val2": "18.00",
          "chgp": "-144.44%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "514.00",
          "val2": "437.00",
          "chgp": "17.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "148.20%",
          "val2": "157.20%",
          "chgp": "-0.90%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 5.84% vs 2.95% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -0.87% vs 1.10% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "16,304.00",
          "val2": "15,405.00",
          "chgp": "5.84%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "3,425.00",
          "val2": "3,383.00",
          "chgp": "1.24%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "733.00",
          "val2": "711.00",
          "chgp": "3.09%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-77.00",
          "val2": "4.00",
          "chgp": "-2,025.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,361.00",
          "val2": "1,373.00",
          "chgp": "-0.87%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "139.90%",
          "val2": "147.30%",
          "chgp": "-0.74%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

4,359.00

3,958.00

10.13%

Operating Profit (PBDIT) excl Other Income

963.00

925.00

4.11%

Interest

193.00

174.00

10.92%

Exceptional Items

-8.00

18.00

-144.44%

Consolidate Net Profit

514.00

437.00

17.62%

Operating Profit Margin (Excl OI)

148.20%

157.20%

-0.90%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 10.13% vs 2.35% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 17.62% vs -6.82% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

16,304.00

15,405.00

5.84%

Operating Profit (PBDIT) excl Other Income

3,425.00

3,383.00

1.24%

Interest

733.00

711.00

3.09%

Exceptional Items

-77.00

4.00

-2,025.00%

Consolidate Net Profit

1,361.00

1,373.00

-0.87%

Operating Profit Margin (Excl OI)

139.90%

147.30%

-0.74%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 5.84% vs 2.95% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -0.87% vs 1.10% in Dec 2024

All Annual Results

Company CV

About IQVIA Holdings, Inc.

IQVIA Holdings, Inc.

Miscellaneous

IQVIA Holdings Inc., formerly Quintiles IMS Holdings, Inc., provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services. The Research & Development Solutions segment provides biopharmaceutical development services. It offers project management and clinical monitoring, clinical trial support services, Q2 solutions, and strategic planning and design. The Integrated Engagement Services segment offerings include healthcare provider engagement services, patient engagement services, and scientific strategy and medical affairs services. The Company has its operations in the Americas, Europe and Africa, and the Asia-Pacific.

Company Coordinates

Company Details

4820 Emperor Blvd , DURHAM NC : 27703-8426

Tel: 1 919 9982000

https://ir.iqvia.com/

Registrar Details